Ranked by engagement
Top topics — all time page 12
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 12 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: State-level differences that actually matter
State-level differences that actually matter — setting out what I have, and where I think it stops being reliable. A follow-up question about State-level differences that I did not know to ask the first time.…
|
+90 | 96 | 4.1k | 4mo |
|
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
|
+71 | 80 | 38k | 11mo |
|
Dead volume across syringe and needle combinations
On the subject in the title: Dead volume across syringe and needle combinations Working notes rather than a conclusion. Something about dead volume across syringe does not reconcile and I would like a second…
|
+72 | 80 | 28k | 5mo |
|
Common supplements people ask about, assessed one at a time — a second dataset
Posting this under the heading it deserves: Common supplements people ask about, assessed one at a time — a second dataset Everything below is what sits behind that. A follow-up question about Common…
|
+97 | 104 | 15k | 3mo |
|
Reconstitution volumes that produce round numbers, tabulated
Reconstitution volumes that produce round numbers, tabulated — setting out what I have, and where I think it stops being reliable. Writing this out with the numbers in it, because "roughly" is how these go…
|
+103 | 112 | 1.7k | 3mo |
|
[2026 update] Travelling with an injectable: documentation and practicalities
Travelling with an injectable: documentation and practicalities Writing it up because I had to work it out twice and would rather nobody else did. Dated regional question, February 2026, because everything in…
|
+107 | 111 | 12k | 1d |
|
Second pass at: Pen dose counters: what a click does and does not guarantee
Second pass at: Pen dose counters: what a click does and does not guarantee — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Pen…
|
+63 | 68 | 51k | 13mo |
|
Payment mechanics and the recovery options that do not exist
Payment mechanics and the recovery options that do not exist Writing it up because I had to work it out twice and would rather nobody else did. A payments question, with the mechanics separated from the…
|
+80 | 89 | 24k | 9mo |
|
Blind submission and why it changes minds
Blind submission and why it changes minds — setting out what I have, and where I think it stops being reliable. What changes if the standard account of blind submission is wrong? I ask because I have been…
|
+91 | 96 | 1.1k | 21mo |
|
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…
|
+92 | 97 | 3.6k | 20h |
|
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem
On the subject in the title: Lateral-flow and colorimetric approaches: the specificity problem Working notes rather than a conclusion. Lateral-flow and colorimetric approaches — I have the observation and I…
|
+77 | 89 | 16k | 9h |
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…
|
+84 | 91 | 18k | 2y |
|
The most useful thing you learned here that was not the answer you came for
The most useful thing you learned here that was not the answer you came for Writing it up because I had to work it out twice and would rather nobody else did. A digression I have been saving for the right…
|
+54 | 61 | 57k | 1d |
|
[2026 update] Does dual agonism explain the effect size, or is it dose?
Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…
|
+58 | 63 | 40k | 9mo |
|
[2026 update] A rising related-substance total over six months: degradation or method drift?
The question in the title: A rising related-substance total over six months: degradation or method drift? I will give what I have already checked below so nobody repeats it. Posting the method first, because…
|
+71 | 78 | 34k | 5mo |
|
Meeting a protein target on a suppressed appetite — does this still hold?
Asking directly, because I could not find a straight answer: Meeting a protein target on a suppressed appetite — does this still hold? Posting a small dataset on Meeting a protein target. It is mine, it is…
|
+56 | 61 | 45k | 19mo |
|
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. SOUL trial and oral semaglutide — I have the observation and I do not trust my…
|
+100 | 104 | 4.2k | 5mo |
|
Documenting a supplier's response to a discrepancy — does this still hold?
Documenting a supplier's response to a discrepancy — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Structured question about turnaround and…
|
+47 | 52 | 58k | 16mo |
|
Endotoxin and why it is a separate question from purity — what changed since
On the subject in the title: Endotoxin and why it is a separate question from purity — what changed since Working notes rather than a conclusion. What changes if the standard account of Endotoxin is wrong? I…
|
+78 | 91 | 1k | 10h |
|
Second pass at: How to ask a question when you cannot say why you are asking it
Second pass at: How to ask a question when you cannot say why you are asking it — setting out what I have, and where I think it stops being reliable. Checking my reasoning rather than asking for a conclusion.…
|
+73 | 81 | 16k | 4mo |
|
Revisiting: Protein density versus volume when you cannot eat much
Revisiting: Protein density versus volume when you cannot eat much Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin Protein density…
|
+97 | 108 | 3.6k | 2d |
|
Measurement error in home scales, with a worked standard deviation — the long version
On the subject in the title: Measurement error in home scales, with a worked standard deviation — the long version Working notes rather than a conclusion. A narrow question about Measurement error in home…
|
+96 | 105 | 2k | 2mo |
|
How to ask about something you suspect is a bad idea
The question in the title: How to ask about something you suspect is a bad idea I will give what I have already checked below so nobody repeats it. Question in the title. Context below, and I have tried to…
|
+81 | 87 | 16k | 2mo |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. Official shortage notices — I have the observation and I do not trust my…
|
+85 | 92 | 5.5k | 11mo |
|
Personal or family history of medullary thyroid carcinoma — what changed since
Posting this under the heading it deserves: Personal or family history of medullary thyroid carcinoma — what changed since Everything below is what sits behind that. Asking about a contraindication as written…
|
+91 | 96 | 1.3k | 25d |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…
|
+85 | 90 | 13k | 7mo |
|
[2026 update] How much of the diluent volume the powder itself displaces
The question in the title: How much of the diluent volume the powder itself displaces I will give what I have already checked below so nobody repeats it. Writing this out with the numbers in it, because…
|
+89 | 100 | 3.2k | 8mo |
|
Airline travel with a temperature-sensitive injectable — what changed since
Airline travel with a temperature-sensitive injectable — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of Airline…
|
+89 | 95 | 5.3k | 9mo |
|
Second pass at: Programming during a large energy deficit
On the subject in the title: Second pass at: Programming during a large energy deficit Working notes rather than a conclusion. The question about Programming during a large energy that I actually want…
|
+94 | 100 | 1.2k | 8mo |
|
Seven-day rolling means and why weekly readings mislead — one year on
On the subject in the title: Seven-day rolling means and why weekly readings mislead — one year on Working notes rather than a conclusion. Asking about Seven-day rolling directly, because I have read four…
|
+78 | 88 | 16k | 5mo |